Aktis Oncology (NASDAQ:AKTS) Issues Quarterly Earnings Results

Aktis Oncology (NASDAQ:AKTS) issued its quarterly earnings data on Wednesday. The technology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.05), FiscalAI reports. The business had revenue of $3.23 million during the quarter, compared to the consensus estimate of $1.85 million.

Aktis Oncology Stock Performance

NASDAQ:AKTS opened at $18.27 on Tuesday. Aktis Oncology has a one year low of $14.72 and a one year high of $29.16. The stock has a 50-day simple moving average of $18.75.

Analyst Ratings Changes

AKTS has been the topic of several analyst reports. TD Cowen started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They set a “buy” rating on the stock. Leerink Partners started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 price objective for the company. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. JPMorgan Chase & Co. started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price on the stock. Finally, William Blair began coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.00.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.